PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company
focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for the
treatment of hypercholesterolemia, today announced the pricing of its
initial public offering of 5,000,000 shares of its common stock at a
price to the public of $14.00 per share. The shares are expected to
begin trading on the NASDAQ Global Market on June 26, 2013 under the
symbol "ESPR." In addition, Esperion has granted the underwriters a
30-day option to purchase up to an additional 750,000 shares of common
stock to cover over-allotments, if any.
Credit Suisse Securities (USA) LLC and Citigroup Global Markets Inc. are
acting as joint book-running managers for the offering. JMP Securities
LLC and Stifel, Nicolaus & Company, Incorporated are acting as
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on June 25, 2013.
When available, copies of the final prospectus relating to the offering
may be obtained by contacting Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, One Madison Avenue, New York, NY
10010, by calling toll-free (800) 221-1037, or by emailing firstname.lastname@example.org;
or Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by email at email@example.com,
by phone at (800) 831-9146.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
Denise Powell, 510.703.9491
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media